Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.

@article{Gordon2004LongtermSA,
  title={Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.},
  author={Alan N. Gordon and Margaret E Tonda and Steven C. Sun and Wayne R Rackoff},
  journal={Gynecologic oncology},
  year={2004},
  volume={95 1},
  pages={1-8}
}
OBJECTIVE Provide long-term follow-up data for women treated in a randomized multicenter study of pegylated liposomal doxorubicin compared with topotecan. METHODS Patients with epithelial ovarian cancer that recurred after or failed to respond to first-line platinum-based chemotherapy were randomized to receive pegylated liposomal doxorubicin 50 mg/m(2) every 28 days (n = 239) or topotecan 1.5 mg/m(2) per day for 5 days every 21 days (n = 235). Patients were stratified prospectively based on… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 124 extracted citations

Update on immune checkpoint inhibitors in gynecological cancers

Journal of gynecologic oncology • 2017
View 5 Excerpts
Highly Influenced

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…